您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Soraprazan(BYK61359)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Soraprazan(BYK61359)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Soraprazan(BYK61359)图片
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
1mg电议
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议

产品介绍
Soraprazan (BYK61359) (BYK61359) 是一种选择性的、可逆的 K 竞争性 H,K-ATPase 抑制剂 (Ki=6.4 nM),在胃腺中的 IC50 为 0.19 μM。

Kinase experiment:

[3H]Soraprazan binding studies are carried out at 20℃. In saturation experiments to determine the Kd value, ion-leaky gastric vesicles (0.01-0.02 mg/mL) are resuspended in a buffer composed of 20 mM Tris-HCl, pH 7.0, 2 mM MgCl2, and 2 mM ATP (pH 7.0 by Tris) in the presence of increasing concentrations of [3H]soraprazan (0.1 nM-1 μM). Nonspecific binding is determined in the presence of a 100 fold excess of unlabeled soraprazan over the concentration range of [3H]soraprazan used. The enzyme suspension (1 mL) is incubated at 20℃ for 30 min and rapidly filtered through a nitrocellulose membrane filter (0.45 μM) prewet with a solution composed of 20 mM Tris-HCl, pH 7.0, 10% polyethylene glycol 3350 that is placed on top of a glass fiber filter. The membrane is ished five times with 2.5 mL of a buffer composed of 20 mM Tris-HCl, pH 7.0, and 10% polyethylene glycol 3350 to remove unbound inhibitor. The membrane is put into a 20-mL scintillation vial, dimethylacetamide (0.5 mL) is added to dissolve the membrane, and 14 mL of scintillation solvent is added and counted. Binding of [3H]soraprazan is determined by subtracting the nonspecific binding of [3H]soraprazan, obtained in the presence of the 100-fold excess of nonradioactive soraprazan, from the amounts of [3H]soraprazan bound to the membrane in the absence of the cold inhibitor.

产品描述

Soraprazan is a reversible, and fast-acting inhibitor of gastric H+/K+ ATPase.

Soraprazan is a potent inhibitor of gastric H,K-ATPase, with an IC50 of 0.1 μM when measured in ion-leaky vesicles in the presence of 1 mM potassium. Soraprazan also effectively inhibits dibutyryl cAMP-stimulated [14C]AP accumulation in isolated gastric glands with an IC50 of 0.19 μM (0.09-0.40 μM geometric mean from n=6 with 95% confidence limits). In ion-leaky vesicles, soraprazan is a potent k-competitive inhibitor of the H,K-ATPase, with Ki of 6.4 nM. Soraprazan binds to the H,K-ATPase in ion-leaky vesicles with a Kd of 26.4 nM and a Bmax of 2.89 nmol/mg[1].

[1]. Simon WA, et al. Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther. 2007 Jun;321(3):866-74. Epub 2007 Mar 16.